ASH 2025: Eli Lilly’s Jaypirca emerges as a strong first-line contender in CLL/SLL
At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December updated results from the global, multi-centre, open-label,…
Industry
-
-
Redefining clinical trials in oncology and rare diseases across the Europe
Later this month, experts from the pharmaceutical and biotechnology industry and patient advocacy space will gather in Munich, Germany, to…
-
ESMO 2025: potential new adjuvant option ensartinib for ALK+ NSCLC
At the 2025 European Society of Medical Oncology (ESMO) Congress, held on 17 to 21 October in Berlin, Germany, results…
-
Asbestos-related cancers still prevalent in the UK
Asbestos is a naturally occurring mineral that is resistant to heat and corrosion. These properties make it suitable for insulation…
-
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer
Imunon’s IL-12 gene therapy IMImuNN-001 converts the tumour microenvironment from “cold” to “hot” by both, halting immunosuppressive makers, and stimulating…
-
Sartorius to invest $3m for minority share in biotech start-up Nanotein
Sartorius Stedim Biotech has agreed to invest $3m in Nanotein Technologies, a US-based company engaged in the development of advanced…
-
GSK’s anti-TIM-3 antibody fails in Phase III NSCLC trial
GSK’s anti-TIM monoclonal antibody (mAb) cobolimab has failed a Phase III trial in non-small cell lung cancer (NSCLC). The COSTAR Lung…
-
JCR Pharma and Alexion partner on JUST-AAV gene therapy platform
JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsids to advance genomic…
-
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
At the 2025 European Hematology Association (EHA) Congress, held from June 12 to June 15 in Milan, Italy, updated results…
-
Implementing pragmatic approaches for the patients and sites in oncology trials
Is the clinical trials field doing enough to centre the needs and concerns of patients in research? That was the…
